Eli Lilly and Company: Psoriasis trials

The registry lists 35 Psoriasis studies with Eli Lilly and Company as lead sponsor. 1 are open to participants now and 28 have results posted.

Phase 1 9Phase 2 8Phase 3 15Phase 4 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)RecruitingNCT06857942Phase 4
• A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT06602219Phase 2Results posted
• A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT06176768Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT05896527Phase 2Results posted
• A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic PsoriasisCompletedNCT03942042Phase 4Results posted
• A Study of Mirikizumab in Participants With Plaque PsoriasisCompletedNCT03718884Phase 1Results posted
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03573323Phase 4Results posted
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)TerminatedNCT03556202Phase 3Results posted
• A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)CompletedNCT03535194Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03482011Phase 3Results posted
• A Study of LY3316531 in Healthy Participants and in Participants With PsoriasisCompletedNCT03418493Phase 1Results posted
• A Study of Ixekizumab in Chinese Participants With Psoriasis VulgarisCompletedNCT03073213Phase 1Results posted
• Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque PsoriasisCompletedNCT03073200Phase 3Results posted
• A Study of Ixekizumab in Participants With Plaque PsoriasisCompletedNCT02993471Phase 1Results posted
• A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT02899988Phase 2Results posted
• A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital PsoriasisCompletedNCT02718898Phase 3Results posted
• A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic TreatmentCompletedNCT02634801Phase 3Results posted
• A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT02561806Phase 3Results posted
• A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT02513550Phase 3Results posted
• A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe PsoriasisCompletedNCT02387801Phase 3Results posted
• A Safety Study of Mirikizumab (LY3074828)CompletedNCT01947933Phase 1Results posted
• Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT01777191Phase 3Results posted
• A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)CompletedNCT01646177Phase 3Results posted
• A Study in Japanese Participants With Moderate-to-Severe PsoriasisCompletedNCT01624233Phase 3Results posted
• A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)CompletedNCT01597245Phase 3Results posted
• A Phase 2b Study of Baricitinib in Participants With Moderate to Severe PsoriasisCompletedNCT01490632Phase 2Results posted
• A Phase 3 Study in Participants With Moderate to Severe PsoriasisCompletedNCT01474512Phase 3Results posted
• A Study in Participants With Moderate to Severe PsoriasisCompletedNCT01107457Phase 2Results posted
• A Study for Adults With Plaque PsoriasisTerminatedNCT01018810Phase 2Results posted
• A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque PsoriasisCompletedNCT06808815Phase 1
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightCompletedNCT06588283Phase 3
• A Study of LY3361237 in Participants With PsoriasisCompletedNCT04975295Phase 1
• A Safety Study of LY3462817 and LY3509754 in Participants With PsoriasisTerminatedNCT04152382Phase 1
• A Study of LY3041658 in Participants With Skin DiseasesCompletedNCT02896868Phase 1
• A Safety and Efficacy Study of DRM02 in Subjects With Plaque PsoriasisCompletedNCT01993433Phase 2